by Michael Nevradakis, Ph.D., Childrens Health Defense:
In 2024, Blackstone, the world’s largest alternative assets manager, launched a $750 million investment in Moderna to support the development of its mRNA flu vaccine. In February, the FDA rejected a review of the vaccine’s Phase 3 clinical trial. By early March, the head of the agency’s vaccine division was gone from the FDA, and the review was back on.
TRUTH LIVES on at https://sgtreport.tv/
In February, the U.S. Food and Drug Administration (FDA) made waves after it declined to review the Phase 3 clinical trial data for Moderna’s mRNA flu vaccine. One week later, the FDA reversed course — and by early March, the agency’s vaccines head, Dr. Vinay Prasad, was gone.
The events occurred amid a broader shift away from vaccine-related messaging — by the Trump administration and the “Make America Healthy Again” (MAHA) movement — leading up to this year’s midterm elections.
The messaging shift disappointed many MAHA activists and led the administration to try to shore up MAHA support.
Some analysts have suggested that polls showing lukewarm public support for stricter vaccine policies contributed to the administration’s decision to pivot away from vaccine messaging.
But some medical freedom advocates have questioned those polls. They suggest instead that lobbying by influential investors — specifically, Blackstone — has more to do with the shift in messaging and policy than public opinion.
Blackstone launched $750 million investment in Moderna
Blackstone, a New York-based investment firm, is the world’s largest alternative assets manager, with a portfolio exceeding $1 trillion. In 2024, the company launched an ongoing, $750 million investment in Moderna, explicitly to support the development of its mRNA flu shot.
Read More @ ChildrensHealthDefense.org
